Performance of the CellaVision advanced RBC application for schistocyte counting in the emergency clinical laboratory.
An AI tool reliably screens for a dangerous blood clotting condition but requires expert review for confirmation, improving speed and reducing human inconsistency.
This prospective validation study across two tertiary-care emergency laboratories assessed the CellaVision ARBCA AI tool for schistocyte quantification in 169 peripheral blood smears, finding strong overall agreement with expert reviewers (no systematic error, high kappa) and perfect specificity for MAHA detection at the 1.62% threshold. While ARBCA is validated as a useful screening and standardization tool—particularly reducing operator variability and turnaround time—its 60% sensitivity in confirmed MAHA cases means expert morphological review remains essential for time-critical thrombotic microangiopathy diagnosis.
What the study was
- Study design
- Prospective diagnostic validation study (two tertiary-care laboratories)
- Population
- Emergency laboratory patients with peripheral blood smears, including MAHA cases (n=169 smears)
- Sample size
- 169
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- Clinical chemistry and laboratory medicine
Why it surfaced
Prospective multicenter validation of AI-based automated schistocyte quantification directly addresses a critical laboratory need for TMA/MAHA diagnosis; high specificity (100%) makes it immediately deployable as a rule-in screen, with the validated limitations clearly characterizing where human review is required.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.